Table 3.

Patient mortality in p27-altered colon cancer (compared with p27-nuclear+ tumor) in strata of BMI

BMI (kg/m2)Colon cancer-specific mortality in p27-altered tumors (vs p27-nuclear+ tumors as a reference)
Overall mortality in p27-altered tumors (vs p27-nuclear+ tumors as a reference)
No. deaths/cases (p27-altered vs p27-nuclear+)Stage-matched HR (95% CI)Multivariate HR (95% CI)No. deaths/cases (p27-altered vs p27-nuclear+)Stage-matched HR (95% CI)Multivariate HR (95% CI)
<2547/188 (25%) vs 18/67 (27%)0.73 (0.42-1.29)0.72 (0.40-1.32)78/188 (41%) vs 27/67 (40%)0.93 (0.59-1.47)0.91 (0.57-1.46)
25-2948/207 (23%) vs 14/40 (35%)0.54 (0.29-1.01)0.50 (0.26-0.99)94/207 (45%) vs 20/40 (50%)0.77 (0.47-1.27)0.67 (0.40-1.14)
≥3018/87 (21%) vs 6/17 (35%)0.40 (0.15-1.06)0.34 (0.12-0.93)29/87 (33%) vs 11/17 (65%)0.31 (0.15-0.65)0.28 (0.13-0.59)
P for interaction (p27 and BMI)*0.400.300.0150.013
  • NOTE: p27-altered tumors include tumors with cytoplasmic p27 localization and tumors with loss of p27 expression. The multivariate, stage-matched conditional Cox model included the p27 variable stratified by BMI, age, year of diagnosis, sex, BMI, family history of colorectal cancer, tumor location, stage, grade, KRAS, BRAF, PIK3CA, p53, p21, cyclin D1, β-catenin, COX-2, FASN, LINE-1 methylation, MSI, and CIMP.

  • * BMI is used as a binary variable (<30 versus ≥30 kg/m2).